Repligen 10-Q: $41.2M Impairment Drives Q3 Loss; Material Weaknesses Persist
RGEN sits 75% above its 52-week low of $100.99 on elevated volume (3.7× avg).
Summary
Repligen's Q3 revenue rose 10.9% to $209.3 million, but a $41.2 million intangible impairment and a $13.7 million divestiture loss drove a $38.4 million net loss; material weaknesses in internal controls remain unremediated.
Key Events · Earnings and Guidance · RGEN
-
Q3 Revenue Grows 10.9% to $209.3M
Total revenue rose to $209.3 million from $188.8 million, with product revenue up 10.9% and nine-month revenue up 12.5% to $607.7 million.
-
$41.2M Intangible Impairment Hits Q3
A non-cash $41.2 million write-down of developed-technology intangibles tied to an IP license agreement, plus a $13.7 million loss on the Polymem sale, drove a $38.4 million net loss ($0.68 per share) versus $14.9 million of income ($0.27) a year earlier.
-
Material Weaknesses Still Unremediated
As of September 30, 2026 the company has not remediated the previously disclosed IT general controls and inventory valuation/financial-close material weaknesses; disclosure controls were concluded not effective.
-
BioLife Deal Closed October 6
The ~$1.9 billion acquisition closed for ~7.2 million Repligen shares plus ~$564 million cash; BioLife holders received $11.25 cash plus 0.1442 Repligen shares per share.
Analysis · RGEN · Life Sciences
Revenue grew 10.9% to $209.3 million in Q3, yet the quarter swung to a $38.4 million net loss ($0.68 per share) from $14.9 million of income a year ago. Two non-cash items did the damage: a $41.2 million impairment of developed-technology intangibles tied to an IP license agreement, and a $13.7 million loss on the Polymem divestiture. The write-down resets the earnings base and signals that at least one licensed technology is not panning out, though it carries no cash impact. More consequential for governance: the previously disclosed material weaknesses in IT general controls and in inventory valuation/financial-close controls remain unremediated as of September 30, 2026, so disclosure controls are still deemed ineffective. Against that backdrop, the company closed the ~$1.9 billion BioLife acquisition on October 6 (7.2 million shares plus ~$564 million cash) and on October 29 launched a $1.0 billion 0.25% convertible note due 2031, exchanging ~$456.8 million of the 2028 notes and raising ~$458.6 million in cash, with ~$120.0 million earmarked to buy back stock. The refinancing lowers coupon cost and pushes maturity out, but the added share repurchase and the BioLife share issuance change the share count picture.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGEN was trading at $176.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2B. The 52-week trading range was $100.99 to $198.87. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.